Catestatin is useful in detecting patients with stage B heart failure

References

• Ammar H, Malani AK, Gupta C, Dobyan DC. (2006). Brain natriuretic peptide, clinical reasoning, and congestive heart failure. Am J Crit Care 15:614–616.
   Google Scholar
• Clerico A, Emdin M. (2004). Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50:33–50.
   PubMed Web of Science ®Google Scholar
• Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, Zyw L, Zucchelli GC. (2005). Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 51:445–447.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. (2003). Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24:1710–1718.
   PubMed Web of Science ®Google Scholar
• de Denus S, Pharand C, Williamson DR. (2004). Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 125:652–668.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. (1986). Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458.
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). (2006). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27:1341–1381.
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. (1990). Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724–1729.
   PubMed Web of Science ®Google Scholar
• Gaede AH, Pilowsky PM. (2010). Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic reflex. Am J Physiol Regul Integr Comp Physiol 299:R1538–R1545.
   Google Scholar
• Goldberg LR, Jessup M. (2006). Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 113:2851–2860.
   PubMed Web of Science ®Google Scholar
• GU Dongfeng, HUANG Guangyong, HE Jiang, Wu Xigui, Duan Xiufang, Stephen MacMahon, Paul K. Whelton. (2003). Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population. Chin J Cardiol 31:3–6.
   Google Scholar
• Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 112:e154–e235.
   Google Scholar
• Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. (2009). 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:e391–e479.
   PubMed Web of Science ®Google Scholar
• Mahapatra NR. (2008). Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 80:330–338.
   PubMed Web of Science ®Google Scholar
• Mahapatra NR, O’Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. (2005). Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115:1942–1952.
   PubMed Web of Science ®Google Scholar
• Mahata SK, Mahata M, Fung MM. (2010). Catestatin: A multifunctional peptide from chromogranin A. Regul Pep 165:52–62.
   Google Scholar
• Mahata SK, Mahata M, Wakade AR, O’Connor DT. (2000). Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol 14:1525–1535.
   PubMedGoogle Scholar
• Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. (1997). Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100:1623–1633.
   PubMed Web of Science ®Google Scholar
• Maisel A. (2002). B - type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 3(Suppl 4):S10–S17.
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. (2007). 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462–1536.
   PubMed Web of Science ®Google Scholar
• Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. (2005). Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 51:2245–2251.
   PubMed Web of Science ®Google Scholar
• O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. (2002). Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335–1345.
   PubMed Web of Science ®Google Scholar
• Pfister R, Schneider CA. (2004). Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta 349:25–38.
   PubMed Web of Science ®Google Scholar
• Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. (2003). Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 49:1552–1554.
   Google Scholar
• Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O’Connor DT. (2007). Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115:2271–2281.
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. (1989). Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367.
   PubMed Web of Science ®Google Scholar
• Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, Mehra MR, Peacock WF , Fonarow G, Gibler WB, Morrow DA, Hollander J; 4th BNP Consensus Panel. (2004). BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10:1–30.
   Google Scholar
• Suzuki T, Yamazaki T, Yazaki Y. (2001). The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 51:489–494.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. (2007). Universal definition of myocardial infarction. Eur Heart J 28:2525–2538.
   PubMed Web of Science ®Google Scholar
• Villars PS, Hamlin SK, Shaw AD, Kanusky JT. (2004). Role of diastole in left ventricular function, I: Biochemical and biomechanical events. Am J Crit Care 13:394–403; quiz 404.
   Google Scholar
• Wang TJ, Levy D, Benjamin EJ, Vasan RS. (2003). The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138:907–916.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu S, Liang Y, Zhu D, Mi L, Wang G, Gao W. (2011). Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers 16:372–377.
   PubMed Web of Science ®Google Scholar
• Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. (2003). 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983–1992.
   PubMed Web of Science ®Google Scholar
• Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, Maisel A. (2002). A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 144:834–839.
   PubMed Web of Science ®Google Scholar
• Wu AH, Smith A. (2004). Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6:355–358.
   PubMed Web of Science ®Google Scholar
• Yancy CW. (2004). The prevention of heart failure in minority communities and discrepancies in health care delivery systems. Med Clin North Am 88:1347–68, xii.
   Google Scholar